The more potent effects of dapagliflozin over empagliflozin for HF outcomes can be explained by the SGLT2:SGLT1 receptor selectivity ratio, which is lower for dapagliflozin (1200:1) than for empagliflozin (2500:1) [35, 36]. Here, SLC5A2 is linked to hydrops fetalis.